Loading
Life sciences · Interventional Study
ClinicalTrials.gov · October 16, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Interventional Study.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Registry record from ClinicalTrials.gov (NCT07879131). This is a study registration, not published results. Lead sponsor: Alexandria University. Recruitment status: NOT_YET_RECRUITING. Phase: NA. Study type: INTERVENTIONAL. Enrollment: 60 participants (ESTIMATED). Conditions: Severe Mental Illness, Bipolar Disorder, Schizophrenia, Schizoaffective Disorder, Major Depressive Disorder. Interventions: BEHAVIORAL: MoodSync; OTHER: Standard care. Primary outcome measures: Manic symptoms - Altman Self-Rating Mania Scale (ASRM) , Baseline and end of the 12-week intervention; Medication adherence - Morisky-Green-Levine Medication Adherence Scale (4 items) , Baseline and end of the 12-week intervention; Practical and social functioning - Practical and Social Functioning Scale (PSF) , Baseline and end of the 12-week intervention; Early warning signs of relapse - Early Signs Scale (ESS) , Baseline and end of the 12-week intervention. Brief summary: The goal of this clinical trial is to learn whether MoodSync, a mobile application for patients and their family caregivers, improves mood stability, medication adherence, daily functioning and early detection of relapse warning signs in adults with severe mental illness in Bahrain. The main question it aims to answer is: Does MoodSync plus standard care improve manic symptoms, medication adherence, practical and social functioning, and early warning signs more than standard care alone? Participants will be randomly assigned to MoodSync plus standard care or standard care alone. MoodSync participants will use the patient app for 12 weeks for daily mood check-ins, sleep and activity tracking with a wearable device, medication reminders, daily-routine (social rhythm) support and early warning-sign reporting. A nominated family caregiver may use the linked caregiver app. All participants continue standard care and complete questionnaires before and after the intervention period. Research hypothesis: \* Patients who use MoodSync will show greater improvement in mood symptoms, medication adherence, practical and social functioning, and relapse-related outcomes than patients receiving standard care alone.